SVNS — Solvonis Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- £17.70m
- £16.06m
- 21
- 11
- 84
- 28
Annual cashflow statement for Solvonis Therapeutics, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 7 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.954 | -2.71 | -3.12 | -1.59 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | 0.008 | 0.872 | 1.29 | 0.487 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 0.646 | -0.64 | 0.413 | -0.027 |
| Change in Accounts Receivable | ||||
| Change in Inventories | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | -0.254 | -2.36 | -1.24 | -1.13 |
| Capital Expenditures | -0.001 | -0.718 | -0.232 | -0.324 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | — | — | — | -0.013 |
| Acquisition of Business | ||||
| Cash from Investing Activities | -0.001 | -0.718 | -0.232 | -0.337 |
| Financing Cash Flow Items | — | -0.34 | 0 | -0.041 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0.8 | 4.13 | 0 | 2.08 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0.559 | 1.04 | -1.49 | 0.602 |